

Visual perceptions induced by intravitreal injections of therapeutic agents

S Charalampidou¹, J Nolan², GO Ormonde¹ and S Beatty^{1,2}

Abstract

Purpose The purpose of this study was to conduct a questionnaire-based survey of subjective visual perceptions induced by intravitreal (IVT) injections of therapeutic agents.

Patients and methods Patients undergoing an IVT injection of ranibizumab, pegaptanib sodium, or triamcinolone acetonide were administered a questionnaire in the immediate post-injection period and at 2 weeks of follow-up.

Results In the immediate post-injection period (75 IVT injections, 75 eyes, 75 patients), lights and floaters were reported after 20 (27%) and 24 (32%) IVT injections, respectively. In comparison, at the 2-week follow-up, the incidence of reported lights (11; 15%) was similar ($P > 0.05$), but the incidence of reported floaters was higher (48; 64%; $P = 0.00$).

Subgroup analysis for various injection subgroups (no previous injection vs previous injection(s) in the study eye; injections in study eyes with good VA (logarithm of minimal angle of resolution [logMAR] ≤ 0.3) vs moderate VA ($0.7 < \log\text{MAR} < 0.3$) vs poor VA ($\log\text{MAR} \geq 0.7$); injections according to pharmacological agent (ranibizumab vs pegaptanib vs triamcinolone acetonide); injections in study eyes with choroidal neovascularization (of various causes) vs study eyes with macular edema (of various causes); and injections in phakic vs pseudophakic eyes) did not reveal any statistically significant associations. Visual perceptions experienced following 15% of IVT injections gave cause for concern to the patient (mean visual analog scale score (\pm SD): 4.5 (\pm 1.7)), and in 64% of cases, the patients believed that preoperative counseling would have averted the concern.

Conclusions Lights and floaters are frequent visual perceptions following IVT injections of

therapeutic agents. They can give rise to concern that could be alleviated with preinjection counseling.

Eye (2011) 25, 494–501; doi:10.1038/eye.2010.229; published online 28 January 2011

Keywords: visual experience; intravitreal injection; anti-vascular endothelial growth factor; triamcinolone; visual perception; questionnaire

Introduction

Intravitreal (IVT) administration of therapeutic agents has become routine practice in ophthalmology in the last decade. IVT injections of antibodies to vascular endothelial growth factor (anti-VEGF), such as ranibizumab (Lucentis, Genentech, San Francisco, CA, USA), pegaptanib sodium (Macugen, OSI/Eyetech and Pfizer, New York, NY, USA) and bevacizumab (Avastin, Genentech), as well as IVT injections of triamcinolone acetonide (Kenalog, Bristol-Myers Squibb, New York, NY, USA), have gained popularity in the treatment of a wide array of ophthalmic disorders, such as choroidal neovascularization (CNV) secondary to neovascular age-related macular degeneration^{1,2} and angioid streaks,³ macular edema (MO) secondary to diabetes mellitus,^{4,5} central retinal vein occlusion,⁶ branch retinal vein occlusion,⁷ uveitis,⁸ pseudophakia,⁹ and telangiectasia.³ Indeed, some authors are even using IVT therapeutic agents for relatively rare disorders, such as central serous chorioretinopathy.³

Patients' visual perceptions and experiences induced by frequently performed ophthalmic surgical procedures, such as cataract surgery (under topical^{10–15} and regional anesthesia^{11–14,16,17}), glaucoma filtration

¹Institute of Eye Surgery and Institute of Vision Research, Whitfield Clinic, Butlerstown North, Waterford, Ireland

²Macular Pigment Research Group, Waterford Institute of Technology, Waterford, Ireland

Correspondence: S Charalampidou, Institute of Eye Surgery and Institute of Vision Research, Whitfield Clinic, Cork Road, Waterford, Ireland
 Tel: +35 387 241 1425;
 Fax: +35 351 319 849.
 E-mail: sonia.sofia1@gmail.com

Received: 23 August 2010
 Accepted in revised form: 22 November 2010
 Published online: 28 January 2011

This study was presented at the 10th Euretina Congress on the 3 September 2010, in Paris, France and at the Irish College of Ophthalmologists' Annual Conference on the 30 April 2010, in Dublin, Ireland.

surgery,¹⁸ and vitreoretinal surgery,^{19–22} are well documented. Indeed, the beneficial effect of preoperative counseling with respect to known and anticipated visual experiences during phacoemulsification cataract surgery, under topical anesthesia, in terms of reducing patients' fear, has been described.²³

However, to our knowledge, there has been no report of patients' subjective visual experiences induced by IVT injections. Awareness of patients' visual experiences in the immediate and early post-injection periods will enhance counseling in the preinjection setting, and may avert unjustified concern in the post-injection period on the part of patients undergoing IVT injections of therapeutic agents.

We have executed and report a questionnaire-based survey, designed to investigate and document visual perceptions induced by IVT injections of therapeutic agents.

Patients and methods

Patients undergoing an IVT injection of ranibizumab, pegaptanib sodium, or triamcinolone acetonide by a single surgeon (SB) between September 2009 and December 2009 were included in the survey. We recruited 82 patients (94 eyes), who underwent a total of 180 consecutive IVT injections and who, following each IVT injection, answered the immediate post-injection questionnaire. Only one injection episode per patient was selected for evaluation (the first one, in cases of serial injections) to avoid subject bias. Each patient was furnished with a detailed information leaflet regarding the risks and benefits of IVT administration of therapeutic agents, including blindness and loss of an eye, and provided written and informed consent for the proposed procedure. Of note, the leaflet did not allude to possible visual perceptions following the injection. Each patient provided informed consent before participating in the questionnaire-based survey. Ethics committee approval was secured from the Local Regional Ethics Committee and the research was conducted in accordance with the tenets of the Declaration of Helsinki.

The IVT injection was performed under direct non-microscopic visualization, under topical anesthesia (single-dose, preservative-free guttae proxymetacaine hydrochloride 0.5% w/v (Minims Proxymetacaine 0.5% Eye Drops, Chauvin, Kingston-upon-Thames, UK)) and using aseptic technique, in accordance with existing consensus guidelines.^{24–26} The pupil was pharmacologically dilated before the IVT injection with single-dose preservative-free guttae cyclopentolate hydrochloride 1% w/v (Minims Cyclopentolate Hydrochloride) and single-dose preservative-free guttae tropicamide 1% w/v (Minims Tropicamide), to allow

visualization of the central retinal artery (CRA) immediately after injection. Visualization of the CRA was achieved using a head-mounted indirect ophthalmoscope until such time, as the pulsatile or perfused status of the optic nerve head was confirmed. All patients were given information on signs and symptoms of endophthalmitis, and other clinically important symptoms, and instructed to present immediately should such symptoms occur. Of note, inadvertent injection of an air bubble was not observed in any of the cases.

An initial questionnaire was administered by the authors, in the immediate post-injection period, and only after confirmation of the pulsatile or perfused status of the CRA (Table 1). It contained three questions, all leading in nature. The first two questions offered 'yes' or 'no' forced-choice alternate options. The last question offered 'better', 'worse', or 'same' forced-choice alternate-options. The person administering the questionnaire covered the patient's other eye for the duration of completion of the questionnaire and asked him/her to keep the injected eye open while answering the questions.

All patients were discharged the same day and routine follow-up was scheduled for 2 weeks following the injection.

At the time of the 2-week follow-up, a second questionnaire was given to the patients (Table 1). The questionnaire was self-administered in the cases in which the patients' visual acuity (VA) allowed them to read it, and administered by the investigators in cases in which the patient's VA prevented him/her from reading the questionnaire. It contained six questions, all leading in nature, relating to visual experiences in the injected eye over the preceding 2 weeks. The first three questions were identical to the ones in the immediate post-injection questionnaire. Of the additional three questions, two questions offered 'yes' or 'no' forced-choice alternate options, and one question offered a visual analog scale (VAS) from 0 to 10 and asked the patients to grade any fear/distress/concern arising from the visual perceptions experienced since the IVT injection.

The mean follow-up was 15.2 days (SD: 2.8; range: 8–26). No intra- or post-operative complications occurred.

Statistical analysis was performed using the software package PASW Statistics 18.0 (IBM Corporations, Somers, NY, USA). The responses to questionnaire items in the immediate and 2-week recollection questionnaires were analyzed for the entire group and for the following injection subgroups: no previous injection *vs* previous injection(s) in the study eye; injections in study eyes with good VA (logarithm of minimal angle of resolution [logMAR] ≤ 0.3) *vs* moderate VA (0.7 < logMAR > 0.3) *vs*

Table 1 Questionnaires

Immediate Post-Injection Questionnaire

Two-Week Follow-up Post-Injection Questionnaire

At any time since your most recent eye injection:

1. Do you see lights?
 No If no, proceed to question 2
 Yes

Are they flashing?
 No
 Yes

Are they colored?
 No
 Yes

If yes, what color? _____

2. Do you see floating objects?
 No If no, proceed to question 3
 Yes

Are they black?
 No
 Yes

Are they colored?
 No
 Yes

If yes, what color? _____

3. How is your vision compared to immediately before the injection?
 Better
 Worse
 Same

At any time since your most recent eye injection:

1. Did you see lights?
 No If no, proceed to question 2
 Yes

Were they flashing?
 No
 Yes

Were they colored?
 No
 Yes

If yes, what color? _____

2. Did you see floating objects?
 No If no, proceed to question 3
 Yes

Were they black?
 No
 Yes

Were they colored?
 No
 Yes

If yes, what color? _____


3. How has your vision been in the eye that received the injection, since your most recent eye injection?
 Better
 Worse
 Same

4. Were you frightened/distressed/concerned by the visual experience following the eye injection?
 No If no, there is no need to answer any more questions
 Yes

If yes, please proceed to question 5

5. How frightened/distressed/concerned were you by the visual experience following the eye injection, on a scale from 0 to 10? (Please encircle a

number between 0 and 10, inclusive)
 0 = no fear/distress/concern at all
 10 = the worse distress/fear ever experienced.



6. If you had been counseled in advance about the possible visual experiences that might follow an intravitreal eye injection, would you have been less frightened/distressed/concerned?
 No
 Yes

Table 2 Comparison of responses to the immediate post-injection and the 2-week recollection questionnaires

| Questions | | Answer | Answers | | P-value |
|---|---|--------------|----------------------------|--------------------------|---------|
| Immediately post-injection | At 2-week recollection | | Immediately post-injection | At 2-week recollection | |
| Do you see lights? (n = 75) | Did you see lights? (n = 75) | Yes | 20 (27%) | 11 (15%) | 0.06 |
| Flashing? (n = 20) | Flashing? (n = 27) | Yes | 11 (55%) | 7 (64%) | 0.56 |
| Colored? (n = 20) | Coloured? (n = 27) | Yes | 13 (65%) | 5 (45%) | 0.56 |
| What colour? (n = 13) | What colour? (n = 14) | Blue/purple | 8 | 1 | |
| | | Silver/white | 4 | 1 | |
| | | Red | 1 | 1 | |
| | | Yellow | 0 | 2 | |
| Do you see floaters? (n = 75) | Did you see floaters? (n = 75) | Yes | 24 (32%) | 48 (64%) | 0.00 |
| Black? (n = 24) | Black? (n = 48) | Yes | 14 (58%) | 41 (85%) | 0.21 |
| Colored? (n = 24) | Colored? (n = 48) | Yes | 8 (33%) | 7 (15%) | 0.32 |
| What colour? (n = 8) | What colour? (n = 7) | Blue/purple | 4 | 3 | |
| | | Silver/white | 2 | 4 | |
| | | Red | 2 | 0 | |
| Vision now compared with vision before injection (n = 75) | Vision now compared with before injection (n = 75) | Better | 7 (10%) | 33 (44%) | 0.00 |
| | | Worse | 49 (65%) | 4 (5%) | |
| | | Same | 19 (25%) | 38 (51%) | |
| — | Concern with visual experience? (n = 75) | Yes | — | 11 (15%) | — |
| — | Would counseling have reduced the concern? (n = 11) | Yes | — | 7 (64%) | — |
| — | VAS score (n = 18) | — | — | Mean (±SD) 4.5 (±1.7) | — |

Abbreviations: SD, standard deviation; VAS, visual analog scale.

poor VA ($\log\text{MAR} \geq 0.7$); injections according to pharmacological agent (ranibizumab vs pegaptanib vs triamcinolone acetonide); injections in study eyes with CNV (of various causes) vs study eyes with MO (of various causes); and injections in phakic vs pseudophakic study eyes. Descriptive statistics were used to analyze the responses to each questionnaire item in the entire group. A series of Wilcoxon signed-rank tests were performed to compare responses immediately after injection and at the 2-week follow-up. A series of χ^2 tests were performed to compare the responses to each questionnaire item in the predefined subgroups, and a one-way analysis of variance was performed to compare the VAS scores between subgroups. A *P*-value of less than 0.05 was considered statistically significant.

Results

After implementation of the exclusion criteria, data from 75 patients (75 eyes), who underwent one IVT injection but completed both questionnaires, were evaluated. The mean (±SD) age was 74.3 (±9.7) years. The male/female ratio was 25:50, and the right eye: left eye ratio was 33:42. In total, 45 patients (60%) had a history of IVT injection(s) before recruitment in the study.

Analysis of entire group

The responses in the entire group, to each questionnaire item, immediately after an IVT injection (*n* = 75), and at the 2-week follow-up (*n* = 75), are given in Table 2. Lights were observed immediately following 27% (20/75) of IVT injections, and were flashing (11/20; 55%) and colored (13/20; 65%) in over half of these cases. The answers at the time of completion of the 2-week recollection questionnaire, with respect to perceived lights, were not statistically different from those reported in the immediate post-injection period (Wilcoxon signed-rank tests: *P* > 0.05 for all).

Floaters were observed immediately after 24/75 (32%) IVT injections, and were black in 14/24 (58%) of these cases and colored in 8/24 (33%) of these cases, with blue and purple being the predominant colors reported. At the time of completion of the 2-week recollection questionnaire, there was a statistically significant increase in the number of IVT injections that had caused floaters, with floaters reported after 64% of IVT injections, compared with only 32% of IVT injections in the immediate post-injection period (Wilcoxon signed-rank tests: *P* = 0.00). The rest of the answers, at the time of completion of the 2-week recollection questionnaire,

with respect to floaters, were not statistically different from those reported in the immediate post-injection period (Wilcoxon signed-rank tests: $P > 0.05$ for all).

At the time of completion of the 2-week recollection questionnaire, visual perceptions experienced following 15% ($n = 11$) of IVT injections had given cause for concern/distress to those undergoing the injection (mean VAS score (\pm SD): $4.5 (\pm 1.7)$), and in 64% of these cases ($n = 7$) it was believed by the patient that preoperative counseling would have alleviated the expressed concern. Finally, the reported quality of vision changed significantly between the immediate post-injection period and the time of completion of the 2-week recollection questionnaire, with better, similar, and worse vision reported following 44, 51, and 5% of injections at the 2-week follow-up, respectively (compared with following 10, 25, and 65% of IVT injections, respectively, immediately after injection; Wilcoxon signed-rank tests: $P = 0.00$).

Subgroup analysis

Subgroup analysis of responses to each questionnaire item was performed for responses given immediately after an IVT injection (Table 3) and for responses given at the time of completion of the 2-week recollection questionnaire (Table 4). Both immediately after an IVT injection and at the time of completion of the 2-week recollection questionnaire, floaters were more likely to be reported in the suspension subgroup (triamcinolone acetonide; 4/6; 67%) than in the clear-agent subgroup (ranibizumab or pegaptanib sodium; 20/69; 29%; χ^2 -test: $P = 0.06$), but the difference was statistically borderline. Similarly, floaters were more likely to be reported by patients receiving an injection for the treatment of MO (7/13; 54%) than by patients receiving an injection for the treatment of choroidal neovascular membrane (17/62; 27%) (χ^2 -test: $P = 0.06$), but again, the difference was statistically borderline. Subgroups did not differ in any other respect of visual perception, either immediately following the IVT injection or at the time of completion of the 2-week recollection questionnaire (χ^2 -test; $P > 0.05$ for all remaining findings).

Discussion

We executed and report a questionnaire-based survey, designed to investigate and document subjective visual perceptions induced by IVT injections of therapeutic agents. We believe that awareness of patients' visual experiences in the immediate and early post-injection periods is important for the purposes of preoperative counseling and informed consent, and to satisfactorily

Table 3 Subgroup analysis for questionnaire responses, completed immediately after an IVT injection

| Questions | Answer | Previous injection(s) | | | CDVA | | | Injected agent | | | Pathology | | | Lens status | | | |
|--|--------|--------------------------------|------------------------------|---------|--------------------|------------------------|--------------------|----------------|----------------------|--------------------|-----------|--------------|-------------|-------------|-----------------|-----------------------|---------|
| | | No previous injection (n = 30) | Previous injections (n = 45) | P-value | Good CDVA (n = 35) | Moderate CDVA (n = 23) | Poor CDVA (n = 17) | P-value | Clear agent (n = 69) | Suspension (n = 6) | P-value | CNV (n = 62) | MO (n = 13) | P-value | Phakic (n = 33) | Pseudophakic (n = 41) | P-value |
| Do you see lights? | Yes | 8 (27%) | 12 (27%) | 1.0 | 9 (26%) | 5 (23%) | 6 (35%) | 0.62 | 19 (28%) | 1 (17%) | 0.56 | 17 (27%) | 3 (23%) | 0.75 | 7 (21%) | 12 (29%) | 0.43 |
| Do you see floaters? | Yes | 9 (30%) | 15 (33%) | 0.76 | 12 (34%) | 6 (26%) | 6 (35%) | 0.76 | 20 (29%) | 4 (67%) | 0.06 | 17 (27%) | 7 (54%) | 0.06 | 11 (33%) | 13 (32%) | 0.88 |
| Vision now compared with vision before the injection | Better | 2 (7%) | 5 (11%) | 0.24 | 1 (3%) | 3 (13%) | 3 (8%) | 0.24 | 7 (10%) | 0 | 0.30 | 6 (10%) | 1 (8%) | 0.00 | 2 (6%) | 5 (12%) | 0.42 |
| | Worse | 23 (77%) | 26 (58%) | | 25 (71%) | 16 (70%) | 23 (64%) | | 46 (65%) | 3 (50%) | | 45 (73%) | 4 (41%) | | 24 (73%) | 24 (59%) | |
| | Same | 5 (16%) | 14 (31%) | | 9 (26%) | 4 (17%) | 10 (28%) | | 16 (23%) | 3 (50%) | | 11 (18%) | 8 (62%) | | 7 (21%) | 12 (29%) | |

Abbreviations: CDVA, corrected distance visual acuity; CNV, choroidal neovascular membrane; IVT, intravitreal; MO, macular edema. Good CDVA (≤ 0.3); moderate CDVA (> 0.3 and < 0.7) and poor CDVA (≥ 0.7).

Table 4 Subgroup analysis of questionnaire responses at 2 weeks after an IVT injection

| Questions | Previous injection(s) | | | CDVA | | | Injected agent | | | Pathology | | | Lens status | | | | |
|---------------------------------|-----------------------|--------------------------------|------------------------------|---------|--------------------|------------------------|--------------------|---------|----------------------|--------------------|---------|--------------|-------------|---------|-----------------|-----------------------|--------------|
| | Answer | No previous injection (n = 30) | Previous injections (n = 45) | P-value | Good CDVA (n = 35) | Moderate CDVA (n = 23) | Poor CDVA (n = 17) | P-value | Clear agent (n = 69) | Suspension (n = 6) | P-value | CNV (n = 62) | MO (n = 13) | P-value | Phakic (n = 33) | Pseudophakic (n = 41) | P-value |
| Did you see lights? | Yes | 8 (27%) | 12 (27%) | 1.0 | 9 (26%) | 5 (23%) | 6 (35%) | 0.62 | 19 (28%) | 1 (17%) | 0.56 | 17 (27%) | 3 (23%) | 0.75 | 7 (21%) | 12 (29%) | 0.43 |
| Did you see floaters? | Yes | 9 (30%) | 15 (33%) | 0.76 | 12 (34%) | 6 (26%) | 6 (35%) | 0.76 | 20 (29%) | 4 (67%) | 0.06 | 17 (27%) | 7 (54%) | 0.06 | 11 (33%) | 13 (32%) | 0.88 |
| Concern with visual experience? | Yes | 5 (17%) | 6 (13%) | 0.69 | 7 (20%) | 2 (9%) | 2 (12%) | 0.46 | 9 (13%) | 2 (33%) | 0.18 | 9 (15%) | 2 (15%) | 0.94 | 6 (18%) | 5 (12%) | |
| Would counseling have helped? | Yes | 3 (60%) | 4 (67%) | 0.90 | 4 (54%) | 2 (100%) | 1 (50%) | 0.64 | 6 (67%) | 1 (50%) | 0.33 | 6 (67%) | 1 (50%) | 0.90 | 3 (50%) | 4 (80%) | 0.45 |
| VAS score | | 4.0 ± 1.9 | 4.7 ± 1.8 | 0.4 | 4.7 ± 1.7 | 3.8 ± 2.1 | 4.5 ± 0.7 | 0.67 | 4.7 ± 1.6 | 3.3 ± 2.1 | 0.22 | 4.7 ± 1.6 | 3.3 ± 2.1 | 0.22 | 4.8 ± 1.8 | 3.9 ± 1.4 | 0.25 |
| | | | (Mean ± SD) | | | | | | (mean) (±SD) | | | | | | | | (mean) (±SD) |

Abbreviations: CDVA, corrected distance visual acuity; CNV, choroidal neovascular membrane; IVT, intravitreal; MO, macular edema. Good CDVA (≤ 0.3); moderate CDVA (> 0.3 and < 0.7) and poor CDVA (≥ 0.7).

address patients' telephone queries in the early post-injection period.

To the authors' knowledge, there are no published reports of visual perceptions following IVT injections of therapeutic agents, although a number of studies have been performed on the visual phenomena experienced by patients during phacoemulsification cataract surgery.¹⁰⁻¹⁷

We report that flashing lights and floaters are commonly experienced by patients immediately following an IVT injection, and that flashes are experienced by almost two-thirds of patients within the first 2 weeks following the procedure. Preinjection VA, clinical indication for the IVT injection, and the nature of the pharmacological agent injected did not influence the visual experiences of patients, although the authors concede that subgroups analysis was limited because of its small size. Of note, visual experiences following 15% of IVT injections gave cause for concern on the part of patients.

It has been postulated that the visual phenomena experienced by patients during phacoemulsification cataract surgery might represent a combination of colored entoptic phenomena, light-induced visual sensations, and afterimages,²⁷ and it is likely that a number of well-described entoptic phenomena²⁸ might be similarly responsible for the visual experiences described by patients after an IVT injection. First, for example, droplets and threads of guttae fusidic acid, a substance, which because of its viscous nature, causes local variation in the refractive index of the cornea, might cause streaks and spots of light,²⁸ as reported by some patients in this study. Of note, the authors do concede that the presence of viscous guttae fusidic acid on the ocular surface immediately after injection (which was part of the post-injection protocol) may have contributed to the blurring of vision reported by some patients in the immediate post-injection period. Moreover, a transient elevation of intraocular pressure immediately after injection (attested to by the pulsatile nature of the CRA of the injected eye) could cause corneal epithelial edema and consequential halos of light.²⁸ Further, vitreous opacities are known to cast umbral shadows on the retina that give rise to positive scotomas, and are reported by patients as floaters, shadows, or chains of bright spots like a string of pearls,²⁸ and this is a well-described effect of an IVT injection of triamcinolone acetonide (which is opaque). However, it is possible that ranibizumab and pegaptanib sodium, even though transparent, would cause local variation in the refractive index of the vitreous, thereby giving rise to similar visual experiences. Also, direct mechanical stimulation of the retina is known to cause a luminous sensation

called a phosphene,²⁸ and it is possible that the mechanical pressure applied locally on the sclera at the point of injection, firstly by the calipers and then by the needle, might induce such phosphenes following an IVT injection. Finally, the light source of the head-mounted indirect ophthalmoscope, used to visualize the CRA at the end of the procedure, could give rise to Purkinje's figures (a percept of the retinal vascular tree, reported by surveyed patients as shadows or cobwebs),²⁸ if the direction of the incident light changed quickly during the examination.

Awareness of the nature and duration of visual phenomena, induced by IVT injections, should represent an important component of patient preinjection counseling, and will facilitate the healthcare worker dealing with patients' queries (by telephone or otherwise) regarding their IVT injection in the preinjection and in the post-injection period. Furthermore, and in an era of falling thresholds for surgical intervention (and associated high expectations of patients), inadequate informed consent remains the most important factor in cases of medico-legal litigation.^{29–31} We believe that knowledge of the nature and duration of visual perceptions attributable to IVT injections, reported here for the first time, will furnish the practicing ophthalmologist with the wherewithal to strengthen the process of informed consent in the preinjection setting.

In conclusion, lights and floaters are frequent visual perceptions following an IVT injection of therapeutic agents. The majority of participants reported that the concern arising from these visual experiences would have been alleviated if they had been counseled before the injection. Hence, the data from this study will inform professional practice and patients' expectations following the procedure alleviate concerns in the immediate and early post-injection periods, and enhance the process of informed consent.

Summary

What was known before

- Floaters are frequent visual perceptions following IVT injections of triamcinolone acetonide.

What this study adds

- Lights and floaters are frequent visual perceptions following IVT injections of ranibizumab, pegaptanib sodium, and triamcinolone acetonide. They can give cause for concern that could be alleviated with pre-injection counseling.

Conflict of interest

The authors declare no conflict of interest.

References

- 1 Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY *et al.* Ranibizumab for neovascular age-related macular degeneration. *N Engl J Med* 2006; **355**(14): 1419–1431.
- 2 Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. *Ophthalmology* 2009; **116**(1): 57–65.e5.
- 3 Lantry LE. Ranibizumab, a mAb against VEGF-A for the potential treatment of age-related macular degeneration and other ocular complications. *Curr Opin Mol Ther* 2007; **9**(6): 592–602.
- 4 Querques G, Bux AV, Martinelli D, Iaculli C, Noci ND. Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema. *Acta Ophthalmol* 2009; **87**(6): 623–630.
- 5 Yilmaz T, Weaver CD, Gallagher MJ, Cordero-Coma M, Cervantes-Castaneda RA, Klisovic D *et al.* Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review. *Ophthalmology* 2009; **116**(5): 902–911; quiz 912–913.
- 6 Gewaily D, Greenberg PB. Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. *Cochrane Database Syst Rev* 2009; (1): CD007324.
- 7 Wroblewski JJ, Wells III JA, Gonzales CR. Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion. *Am J Ophthalmol* 2010; **149**(1): 147–154.
- 8 Cervantes-Castaneda RA, Giuliani GP, Gallagher MJ, Yilmaz T, MacDonell RE, Quinones K *et al.* Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up. *Eur J Ophthalmol* 2009; **19**(4): 622–629.
- 9 Cervera E, Diaz-Llopis M, Udaondo P, Garcia-Delpech S. Intravitreal pegaptanib sodium for refractory pseudophakic macular oedema. *Eye* 2008; **22**(9): 1180–1182.
- 10 Ang CL, Au Eong KG, Lee SS, Chan SP, Tan CS. Patients' expectation and experience of visual sensations during phacoemulsification under topical anaesthesia. *Eye* 2007; **21**(9): 1162–1167.
- 11 Tranos PG, Wickremasinghe SS, Sinclair N, Foster PJ, Asaria R, Harris ML *et al.* Visual perception during phacoemulsification cataract surgery under topical and regional anaesthesia. *Acta Ophthalmol Scand* 2003; **81**(2): 118–122.
- 12 Rengaraj V, Radhakrishnan M, Au Eong KG, Saw SM, Srinivasan A, Mathew J *et al.* Visual experience during phacoemulsification under topical versus retrobulbar anesthesia: results of a prospective, randomized, controlled trial. *Am J Ophthalmol* 2004; **138**(5): 782–787.
- 13 Chung CF, Lai JS, Lam DS. Visual sensation during phacoemulsification and intraocular lens implantation using topical and regional anesthesia. *J Cataract Refract Surg* 2004; **30**(2): 444–448.
- 14 Tan CS, Au Eong KG, Kumar CM. Visual experiences during cataract surgery: what anaesthesia providers should know. *Eur J Anaesthesiol* 2005; **22**(6): 413–419.
- 15 Yaylali V, Yildirim C, Tatlipinar S, Demirlen I, Arik S, Ozden S. Subjective visual experience and pain level during phacoemulsification and intraocular lens implantation under topical anesthesia. *Ophthalmologica* 2003; **217**(6): 413–416.

- 16 Prasad N, Kumar CM, Patil BB, Dowd TC. Subjective visual experience during phacoemulsification cataract surgery under sub-Tenon's block. *Eye* 2003; **17**(3): 407–409.
- 17 Wickremasinghe SS, Tranos PG, Sinclair N, Andreou PS, Harris ML, Little BC. Visual perception during phacoemulsification cataract surgery under subtenons anaesthesia. *Eye* 2003; **17**(4): 501–505.
- 18 Riad W, Tan CS, Kumar CM, Au Eong KG. What can patients see during glaucoma filtration surgery under peribulbar anesthesia? *J Glaucoma* 2006; **15**(5): 462–465.
- 19 Vohra SB, Anya C, Farooq T, Murray PI. Subjective visual perceptions during vitreoretinal surgery under local anaesthesia. *Eye* 2009; **23**(9): 1831–1835.
- 20 Tan CS, Mahmood U, O'Brien PD, Beatty S, Kwok AK, Lee VY et al. Visual experiences during vitreous surgery under regional anesthesia: a multicenter study. *Am J Ophthalmol* 2005; **140**(6): 971–975.
- 21 Sugisaka E, Shinoda K, Sano RY, Ishida S, Imamura Y, Ozawa Y et al. Mechanism of visual sensations experienced during pars plana vitrectomy under retrobulbar anesthesia. *Ophthalmologica* 2009; **224**(2): 103–108.
- 22 Kawaguchi N, Inoue M, Sugisaka E, Shinoda K, Tsubota K. Subjective visual sensation during vitrectomy under retrobulbar anesthesia. *Am J Ophthalmol* 2006; **141**(2): 407–409.
- 23 Voon LW, Au Eong KG, Saw SM, Verma D, Laude A. Effect of preoperative counseling on patient fear from the visual experience during phacoemulsification under topical anesthesia: multicenter randomized clinical trial. *J Cataract Refract Surg* 2005; **31**(10): 1966–1969.
- 24 Aiello LP, Brucker AJ, Chang S, Cunningham Jr ET, D'Amico DJ, Flynn Jr HW et al. Evolving guidelines for intravitreal injections. *Retina* 2004; **24**(5 Suppl): S3–S19.
- 25 Bylsma G, Guymer R, Qureshi S, Gin T, Allen P, Madhok P et al. Intravitreal injections. *Clin Experiment Ophthalmol* 2006; **34**(4): 388–390.
- 26 Rodrigues EB, Meyer CH, Grumann Jr A, Shiroma H, Aguni JS, Farah ME. Tunneled scleral incision to prevent vitreal reflux after intravitreal injection. *Am J Ophthalmol* 2007; **143**(6): 1035–1037.
- 27 Sumich PM, Francis IC, Kappagoda MB, Alexander SL. Artist's impression of endocapsular phacoemulsification surgery. *J Cataract Refract Surg* 1998; **24**(11): 1525–1528.
- 28 Kaufman PL, Alm A. *Adler's Physiology of the Eye: Clinical Application*, 10th edn. Mosby: St Louis, MO, 2003.
- 29 Reynard J, Marsh H. Unusual and not so unusual ways of ending up in court: how to avoid litigation. *BJU Int* 2009; **104**(5): 586–589.
- 30 Brosnam T, Perry M. 'Informed' consent in adult patients: can we achieve a gold standard? *Br J Oral Maxillofac Surg* 2009; **47**(3): 186–190.
- 31 Olumide Olufowote J. A structural analysis of informed consent to treatment: (re)productions of contradictory sociohistorical structures in practitioners' interpretive schemes. *Qual Health Res* 2009; **19**(6): 802–814.